written by reader What’ Motley Fool’s new double down stock.

by backoffice | March 27, 2016 1:56 pm

What is David’s latest recommendation Travis?
Thanks!

Source URL: https://www.stockgumshoe.com/2016/03/microblog-what-motley-fools-new-double-down-stock/


29 responses to “written by reader What’ Motley Fool’s new double down stock.”

  1. bree moseman says:

    I’ve filled out everything requested but still have not gotten any results regarding my question. Is this how this site always works?

  2. Another Fool says:

    Hey Bree, I’m in your court. The Motley Fool ads are everywhere. I hate these kind of come-ons. I’d also like to know this latest recommendation.

    Here’s one claim and the ad site: “Motley Fool Issues Rare “Double Down” Stock Alert… Past “double downs” have averaged remarkable 598% returns…” https://us-mg6.mail.yahoo.com/neo/b/message?sMid=2&fid=Trash&sort=date&order=down&startMid=0&filterBy=&ac=M1jsHoWU6o_NZYV6BbPtw8r1xUM-&.rand=1892930494&midIndex=2&mid=2_0_0_4_55956_AMXmjkQAADcQVvpvpwii8PIxPy8&fromId=

  3. Sorry, they don’t drop even a single hint as to which company Gardner might be re-recommending in those ads — he does do those “Double Downs” with some frequency, a lot of his most famous past recommendations have been re-recommended several times over the years, but without any hints the Thinkolator isn’t much good at identifying the stock.

  4. db says:

    Probally AVXL

  5. I’m doubling down on OGRMF ! What do you guys think ?

  6. Mike Kapella says:

    The Gardner double down is ilmm illumina, the San Diego based genetic sequencing giant. ilmm has just created Grail, a new start-up of which they own 50%, that seeks to detect cancer from liquid biopsies. They tapped former Jeff Huber, a Google executive, to be the CEO. Jeff Bezos & Bill Gates also own a significant part of this private company. If GRAIL is successful and are able to detect the DNA from stage 1 Cancer revenues can be expected to be $200 billion a year. If their biopsies can detect Stage 2 Cancer revenues can be expected to be $20 billion a year. Illumina also has created Helix in partnership with Warburg Pincus & John Hopkins that will offer consumer driven diagnostic better than 23&me. Incidentally illumina owns a percentage of 23&me a privately held company started by Google founders ex-wife Ann Wojecki. Illumina is an octopus in the biotech industry. The smart money in Silicon Valley, and Wall Street see illumina becoming “The most Important Company in the History of Medicine.” This company should easily double or triple in value within the next 18-24 months. If GRAIL’s biopsy business gets through the FDA, expect the company to grow 10 fold. GRAIL is not Theranos, it has the killer app.

  7. DK says:

    Glad I didn’t buy back on the 18th when the made the recommendation.

  8. Mark says:

    Just like other Motley Fool recommendations that I have purchased, this one is currently down 23%.

  9. Mike says:

    Stock got crushed beyond belief today

  10. Steve says:

    23% down. Great recommendation, DAVE

  11. It should be OGRMF it’s taking off ! Canada plans on legalizing pot by spring 2017

  12. Jackoli says:

    Yea it seems that when the big dogs got into this stock it was already fairly cheap and right now it has already gone up quite a bit. I will be watching for it to dip back down then purchasing a bit since it’s still.pretty high even a couple days later. Most likely until they hit the ” holy grail” I am sure plenty of people will get disenfranchised and there will be plenty of opportunities to buy at a reasonable price.

  13. Brennan Duke says:

    If you buy a stock after the article comes out, you’re usually way too late. They slam the stock waaaay before they start doing advertisement articles for it; then sell as you buy… rinse and repeat.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.